Want to see SE:BACTI.B full AI Analyst Report?
Top Page
Bactiguard Holding AB
(BACTI.B)
Select Model
Select Model
Rating:51Neutral
Price Target:
kr18.00
▼(-6.74% Downside)
Action:Reiterated
Date:08/29/26
The score is driven primarily by improving but still subpar financial performance: positive EBITDA and TTM cash generation are offset by continued net losses and margin pressure. Technicals are moderately supportive with price above key moving averages, but overbought RSI and a slightly negative MACD temper the outlook. Valuation is a headwind due to the negative P/E and lack of dividend yield data.
Positive Factors
Operating Recovery
A positive EBITDA margin indicates that operating cost control has improved materially from the heavy losses seen in 2022–2023. This provides a stronger base for future profitability if revenue quality and gross margins stabilize.
Negative Factors
Persistent Net Losses
Despite improved EBITDA, the company has not yet converted operations into positive EBIT or net income. Persistent losses constrain internal capital formation and indicate that restructuring, financing or stronger commercial execution is still required.
Read all positive and negative factors
Positive Factors
Negative Factors
Operating Recovery
A positive EBITDA margin indicates that operating cost control has improved materially from the heavy losses seen in 2022–2023. This provides a stronger base for future profitability if revenue quality and gross margins stabilize.
Read all positive factors
Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr632.54M
Dividend YieldN/A
Average Volume (3M)77.61K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth-13.72%
EPS Growth52.47%
CountrySE
Employees164
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding31,043,884
10 Day Avg. Volume120,571
30 Day Avg. Volume77,614
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)kr210.28M
Bactiguard Holding AB Business Overview & Revenue Model
Company Description
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HA...
How the Company Makes Money
Bactiguard makes money primarily by monetizing its BIP coating technology and, to a lesser extent, through sales of coated medical devices. A central revenue stream is licensing: Bactiguard enters agreements with medical device companies that inte...
Bactiguard Holding AB Financial Statement Overview
Summary
Income Statement
43
Neutral
Balance Sheet
58
Neutral
Cash Flow
51
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 205.08M | 215.92M | 243.68M | 203.99M | 223.56M | 169.49M |
| Gross Profit | 86.99M | 184.65M | 207.71M | 139.98M | 180.14M | 130.80M |
| EBITDA | 38.61M | 45.15M | 24.99M | -89.98M | -543.00K | -5.94M |
| Net Income | -8.76M | -7.84M | -29.82M | -138.38M | -52.88M | -58.77M |
Balance Sheet | ||||||
| Total Assets | 522.85M | 545.06M | 655.91M | 662.17M | 807.70M | 849.29M |
| Cash, Cash Equivalents and Short-Term Investments | 43.52M | 44.26M | 116.73M | 123.22M | 197.73M | 217.59M |
| Total Debt | 157.09M | 162.92M | 227.77M | 233.10M | 238.70M | 247.96M |
| Total Liabilities | 218.40M | 230.13M | 327.57M | 309.00M | 311.99M | 307.84M |
| Stockholders Equity | 304.45M | 314.93M | 328.34M | 353.18M | 495.71M | 541.45M |
Cash Flow | ||||||
| Free Cash Flow | 8.56M | -7.21M | 10.21M | -60.94M | -7.86M | -38.00K |
| Operating Cash Flow | 13.90M | -1.49M | 24.99M | -52.33M | 3.06M | 7.26M |
| Investing Cash Flow | -5.34M | -5.72M | -14.78M | -8.61M | -10.92M | -7.29M |
| Financing Cash Flow | -13.02M | -62.74M | -21.20M | -11.84M | -13.89M | 205.83M |
Bactiguard Holding AB Technical Analysis
Positive
19.30
Price Trends
15.86
Positive
16.38
Positive
16.54
Positive
Market Momentum
-0.16
Negative
70.07
Negative
32.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Positive. The current price of 19.3 is above the 20-day moving average (MA) of 15.53, above the 50-day MA of 15.86, and above the 200-day MA of 16.54, indicating a bullish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 70.07 is Negative, neither overbought nor oversold. The STOCH value of 32.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr67.38B | 24.81 | 8.88% | 2.06% | -3.56% | 79.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr632.54M | -70.83 | -2.84% | ― | -13.72% | 52.47% | |
48 Neutral | kr232.01M | -4.54 | -27.27% | ― | 0.31% | -26.18% | |
44 Neutral | kr557.33M | -5.01 | -37.43% | ― | 27.40% | 26.07% | |
42 Neutral | kr417.06M | -8.10 | ― | ― | -2.61% | -0.28% |
* Healthcare Sector Average
SE:BACTI.B
Bactiguard Holding AB
17.00
-10.20
-37.50%
SE:GETI.B
Getinge
243.90
39.32
19.22%
SE:SEZI
Senzime AB
3.56
-2.85
-44.45%
SE:INTEG.B
Integrum AB Class B
8.80
-32.97
-78.93%
SE:PRO
Promimic AB
9.10
-5.30
-36.81%
SE:OSSD
OssDsign AB
3.67
-12.02
-76.63%
Bactiguard Holding AB Corporate Events
Bactiguard Adjusts Share Structure to Support 2026 Incentive Plan
Jul 31, 2026
Bactiguard Holding AB, a Stockholm-based MedTech firm listed on Nasdaq Stockholm’s Small Cap segment, develops noble metal coating technologies that prevent infections on medical devices and offers wound care products across orthopedics, car...
Bactiguard deepens BD partnership as Q2 sales and wound care growth strengthen outlook
Jul 14, 2026
Bactiguard reported solid second-quarter 2026 momentum, with total revenue up 9% to SEK 57.1 million and net sales rising 16% adjusted for currency, driven by a strong rebound in BD-related business and record performance in its Wound Management p...
Bactiguard Issues and Repurchases Class C Shares to Fund 2026 Incentive Plan
Jul 8, 2026
Bactiguard Holding AB’s board has moved to secure share delivery under its long-term incentive plan for 2026 by issuing and immediately repurchasing 715,000 Class C shares. The transaction follows authorisations granted at the May annual gen...
Bactiguard to Present Q2 2026 Interim Report in Investor Audiocast
Jul 7, 2026
Bactiguard Holding AB will publish its interim report for the second quarter of 2026 on 14 July at 07:00 CET, followed by an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind and CFO Patrick Bach will present the result...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.